Preclinical WebsiteClinical Website
Table of Contents

Table of Contents

Abstract
01. Presentation Overview
Presentation
01. Introduction02. Regional Volumes Analysis Methods03. Cortical Thickness Analysis Methods04. TDP-43 Model05. TDP-43 Model MR Images06. TDP-43 Model MRI Analysis07. Alpha-Synuclein Model08. Synuclein Model MR Images09. Synuclein Model MRI Analysis10. Summary

Regional Volumes

Brain volumes in Posterior Motor Cortex
Brain volumes in Hippocampus
Brain volumes in Cerebellum

Brain volumes in various cortical and subcortical regions. The arrows show the progression of Off Dox mice that either continued off doxycycline until 6 weeks or were put back on doxycycline for 3 weeks.  * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 

Cortical Thickness

Cortical Thickness in Posterior Motor Cortex
Cortical Thickness in Frontal Cortex

Cortical thickness measures in the motor and frontal cortical regions. The arrows show the progression of Off Dox mice that either continued off doxycycline until 6 weeks or were put back on doxycycline for 3 weeks.  * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 

Cortical thickness map demonstrating the regions of cortical thinning in Low Dox compared to control mice. The colder colors (e.g. blue, purple) represent areas with significant atrophy. Note the high degree of specificity for the motor and frontal cortex at 8 weeks following disease initiation.

--:--

We have been able to show highly significant brain atrophy in this model. In the Off Dox model, we see a rapidly progressive brain atrophy in the motor cortex volume and thickness, frontal cortex thickness, and hippocampal volume.

In contrast, in the slower Low Dox model, we see early changes in the cortical regions, without significant atrophy in the subcortical areas. This finding aligns well with the distribution of TDP-43 pathology. 

Note that the cerebellum is largely spared from brain atrophy. Also, note that putting mice back on Dox effectively halts the neurodegeneration, thereby demonstrating the ability to achieve disease modification in this model. 

We use necessary cookies to make our site work. We also use other cookies to help us make improvements by measuring how you use the site or for marketing purposes. You have the choice to accept or reject them all. For more detailed information about the cookies we use, see our Privacy Notice.